ProCE Banner Activity

CME

Applying Current Precision Medicine Strategies for the Treatment of Gynecologic Cancers

Video

Watch this on-demand webcast from a June 2023 symposium to learn from expert gynecologic oncologists David Scott Miller, MD, FACOG, FACS; Hye Sook Chon, MD; and Domenica Lorusso, MD, PhD, about achieving precision medicine for your patients with gynecologic cancers, including new clinical data, managing adverse events with novel agents, and ongoing trials of interest presented at the annual meeting.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 22, 2023

Expiration: June 21, 2024

No longer available for credit.

Share

Faculty

Hye Sook Chon

Hye Sook Chon, MD

Associate Professor
Clinical Trial Medical Director
Department of Gynecologic Oncology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Domenica Lorusso

Domenica Lorusso, MD, PhD

Full Professor of Obstetrics and Gynecology
Humanitas University
Head of Gynecology Oncology Medical Unit
Humanitas Hospital San Pio X
Milan, Italy

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Eisai, GSK, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

AstraZeneca

Eisai

GSK

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for medical oncologists and other healthcare professionals treating patients with gynecologic cancers.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in using evidence-based and guideline-directed best practices in caring for patients with gynecologic cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment strategies for patients with cervical, endometrial, and ovarian cancers, considering the available clinical data, expert recommendations, and patient preferences

  • Select optimal maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings

  • Individualize immune checkpoint inhibitor–based therapy in endometrial and cervical cancer based on unique tumor and patient characteristics

  • Integrate novel and emerging antibody–drug conjugates into the management of patients with gynecologic malignancies considering available evidence, expert guidance, and individual patient and tumor characteristics

  • Identify populations of patients who are at increased risk for poor prognosis and proactively provide inclusive education and support throughout all stages of diagnostic and treatment regimens

  • Implement evidence-based supportive care for treatment-related symptoms experienced by patients with gynecologic cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Hye Sook Chon, MD

Associate Professor
Clinical Trial Medical Director
Department of Gynecologic Oncology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Hye Sook Chon, MD, has no relevant financial relationships to disclose.

Domenica Lorusso, MD, PhD

Full Professor of Obstetrics and Gynecology
Humanitas University
Head of Gynecology Oncology Medical Unit
Humanitas Hospital San Pio X
Milan, Italy

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme.

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

David Scott Miller, MD, FACOG, FACS: consultant/advisor/speaker: Agenus, AstraZeneca, Asymmetric, Eisai, Eisai Europe Limited, EMD Serono, GlaxoSmithKline, Immunogen, Incyte, iTeos Belgium SA, Karyopharm, Merck Sharp & Dohme, Myriad, Novartis, Novocure, Seagen, Tarveda Therapeutics; researcher (paid to institution): Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, Immunogen, Incyte, Janssen, Karyopharm, Mateon, Merck Sharp & Dohme, Millenium, NVision, Novartis, Pfizer, Regeneron, Syros, Tesaro, Tracon, US Biotest, Xenetic; researcher: EMD Serono Research & Development, Leap.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 22, 2023, through June 21, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.